Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy

Inclusion Criteria: 1. Is between 20 and 80 years of age, inclusive. 2. Patients who are within ±3 days of initiating EGFR inhibitor therapy using afatinib or erlotinib, and have no prior history of using afatinib or erlotinib within 6 months. 3. Has a life expectancy of at least three months. Exclusion Criteria: 1. Has any active dermatological conditions of the face that may interfere with the diagnosis, assessment, or treatment of face skin rash associated with targeted cancer therapy. 2. Has been treated with steroids (systemic or topical on face) to the face within 7 days prior to Day 1. 3. Patients who have been treated with oral antibiotics that known to exert anti-inflammatory effect (such as doxycycline or minocycline) within 7 days prior to Day 1. 4. Is currently treated with target therapy other than afatinib or erlotinib. 5. Receive prior treatment with any investigational product within 28 days prior to Day 1. 6. Has hypersensitivity or allergy to the study medication. 7. Has any other significant diseases, conditions, or laboratory values which, in the opinion of the investigator, might make participation not in the subject's best interest or confound the interpretation of study results.